American journal of ophthalmology case reports · 2025
Netarsudil-associated conjunctival pigmentation.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Azargui Soufiane, Karanxha Joana, Oliver Scott Cn, Kahook Malik Y, Capitena Young Cara E
Аннотация
PURPOSE: To present a case of conjunctival pigmentation associated with topical use of netarsudil 0.02 % (Rhopressa, Alcon, Fort Worth, TX).
OBSERVATION: Bilateral conjunctival pigmentation and cornea verticillata developed after 21 months of initiating netarsudil treatment. The appearance of the conjunctival pigmentation mimicked primary acquired melanosis. Both the conjunctival and corneal findings resolved 14 months after stopping the medication.
CONCLUSION: While the correlation between netarsudil use and corneal verticillata is well-established, we could not identify prior reports of such an association with conjunctival pigmentation. Eye care professionals prescribing netarsudil should be aware of this potential sequela of therapy.
OBSERVATION: Bilateral conjunctival pigmentation and cornea verticillata developed after 21 months of initiating netarsudil treatment. The appearance of the conjunctival pigmentation mimicked primary acquired melanosis. Both the conjunctival and corneal findings resolved 14 months after stopping the medication.
CONCLUSION: While the correlation between netarsudil use and corneal verticillata is well-established, we could not identify prior reports of such an association with conjunctival pigmentation. Eye care professionals prescribing netarsudil should be aware of this potential sequela of therapy.